The contract research organization (CRO) industry has grown in response to demand by biopharmaceutical and medical device companies for Phase I-IV clinical services.
Chief Enrollment Officer
The demand reflected sponsor capacity shortfalls.
When a sponsor lacked sufficient internal resources for a study or program they would look outside the company for a qualified service provider.
As the global clinical research industry evolved, CROs were tasked with supporting a broad range of Phase I-IV clinical trial activities.
In response, many adopted a full-service model that allowed them to support the entire study process.
to read more about the history of the CRO industry.
to read more about Integrium's full-service clinical support.
The dynamics of the global clinical research market continue to evolve. For example, some small and mid-size biotech companies now plan to conduct Phase I-II research using in-house expertise.
Funding for research is often provided by outside investors who have access to capital but lack the insights they need to find common goals that bridge their interests with the interests of biotechs.
Linkage is important because capital providers and biotechs - both of whom are venture-backed - are under financial pressure.
Nearly Full Circle
This new (and urgent) demand to link outside capital with researchers represents a genuine paradigm shift. To fulfill their commitment to being full-service, CROs are challenged to expand their definitions of who they are and what their clients need.
Integrium is a great example of how a company can successfully adapt to change.
We looked carefully at how small biotechs are navigating today's research environment. We found, for example, that many are staffed with ex-CRO veterans with highly specialized skills and networks.
With sufficient internal resources, some biotechs now prefer to provide their own services. To bridge the gaps, we offer stand alone services.
Click here to contact Integrium.